Evidence map›Paper›PMID 41282902›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Tumor

Bala Theivanthiran, Nagendra Yarla, Kaylee Villareal, Y-Van Nguyen, Linda Cao, Ernesto P Calderin, Michael P Plebanek, Kyra Majors, Emily Bolch, Douglas B Johnson and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Bala Theivanthiran
Nagendra Yarla
Kaylee Villareal
Y-Van Nguyen
Linda Cao
Ernesto P Calderin
Michael P Plebanek
Kyra Majors
Emily Bolch
Douglas B Johnson
Hope Uronis
John H Strickler
Nicholas C DeVito
Brent A HanksORCID 0000-0002-2803-3272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy resistance remains a major challenge in immuno-oncology. We have previously demonstrated that a tumor-intrinsic NLRP3 inflammasome signaling pathway promotes adaptive immunotherapy resistance by inducing the recruitment of granulocytic myeloid-derived suppressor cells. We now confirm that elevated tumor NLRP3 signaling activity correlates with checkpoint inhibitor resistance in several independent cohorts of stage III and IV melanoma patients, as well as in advanced gastroesophageal (GE) adenocarcinoma patients.

Identifiers

PMID41282902
PMCPMC12632675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.